Form 4: Tarsus Pharmaceuticals CEO Bobak Azamian Exercises Stock Options
SEC Form 4
Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc., reports the acquisition of common stock through the exercise of restricted stock units.
Summary
- On March 15, 2025, Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, exercised restricted stock units (RSUs) to acquire common stock.
- The transactions involved the vesting and settlement of RSUs granted in 2022, 2023, and 2024 under the company's 2020 Stock Plan.
- Azamian directly acquired 51,395 shares of common stock through the exercise of these RSUs.
- Following the reported transactions, Azamian directly owns 77,851 shares and indirectly owns 830,106 shares through the Bobak Azamian Living Trust.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The exercise of options could be seen as a slightly positive signal, but it's a routine part of executive compensation.
Positives
- The exercise of RSUs by the CEO could be interpreted as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the holdings of key personnel.
Comparison to Industry Standards
- Executive compensation packages including stock options and RSUs are standard practice in the pharmaceutical industry to incentivize performance and align management interests with shareholders.
- Vesting schedules of 25% per year are also common to ensure long-term commitment from executives.
- Comparing Azamian's total holdings to those of CEOs at similarly sized pharmaceutical companies would provide a benchmark for assessing the magnitude of his stake.
Stakeholder Impact
- The transaction has a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| April 16, 2018 | Date the Bobak Azamian Living Trust was established. |
| March 9, 2022 | Date of RSU grant under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, vesting 25% annually starting March 15, 2023. |
| March 8, 2023 | Date of RSU grant under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, vesting 25% annually starting March 15, 2024. |
| March 7, 2024 | Date of RSU grant under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, vesting 25% annually starting March 15, 2025. |
| March 15, 2025 | Date of the reported transaction where RSUs were exercised. |
| March 18, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.